Read our latest technical article on the reannotation and redesign of our self-delivering Accell siRNA.
4 result(s)
Revvity’s Dharmacon™ CRISPR portfolio expands with validated CRISPR guide RNAs for complex but critical gene targets, as well as DNA cutting controls for screen normalization in sensitive assays.
Accell siRNA has been widely literature-cited for gene silencing in primary immune cells, which have historically been difficult to transfect. Learn more here.
Can base editing move cancer cell therapy further towards off-the-shelf treatments?